German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults

Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1)

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00199017

Enrollment

Registered

2005-09-20

Start date

2004-04-30

Completion date

Unknown

Last updated

2010-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, Lymphoblastic

Keywords

T-LBL, Treatment, De novo, Chemotherapy, Adult, Lymphoma, lymphoblastic, T-cell

Brief summary

This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma (T-LBL) according to a protocol for acute lymphoblastic leukemia. Patients receive one year of intensive cyclical chemotherapy with additional prophylaxis for central nervous system (CNS) relapse by intrathecal therapy and cranial irradiation and mediastinal irradiation after induction chemotherapy.

Interventions

PROCEDURECNS irradiation

DRUGDexamethasone/Prednisolone

DRUGCyclophosphamide

DRUGVincristine

DRUGDaunorubicin

DRUGAsparaginase

DRUGG-CSF

DRUGMercaptopurine

DRUGCytarabine

DRUGMethotrexate

DRUGVP16

DRUGVindesine

DRUGAdriamycin

DRUGThioguanine

DRUGHDARAC

PROCEDUREMediastinal irradiation

DRUGCladribine

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

15 Years to 65 Years

Healthy volunteers

Inclusion criteria

* T-lymphoblastic lymphoma (bone marrow \[BM\] involvement \< 25%) * Aged 15-65 years (55-65 years if biologically younger) * Written informed consent

Exclusion criteria

* Severe complications due to lymphoma or secondary disease * T-LBL as second malignancy or other active second malignancy * Cytostatic pretreatment of LBL (exception of emergency treatments) * Pregnancy * Severe psychiatric illness or other circumstances which may compromise cooperation of the patient or informed consent * Participation in other study interfering with study treatment

Design outcomes

Primary

Measure	Time frame
remission rate, remission duration, disease free survival, overall survival	—

Secondary

Measure	Time frame
time and dose compliance, toxicity according to World Health Organization (WHO)	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026